CureVac N.V. (CVAC) Shareholder/Analyst Call Prepared Remarks Transcript

CureVac convened an Extraordinary General Meeting on November 25, 2025 to vote on resolutions tied to BioNTech's public exchange offer for all outstanding CureVac shares, including a post-offer corporate reorganization and the appointment of new Management and Supervisory Board members. The meeting, chaired by Supervisory Board member Mehdi Shahidi due to the chairman's health-related absence, reported 156,246,488 shares represented (approximately 70.52% of issued share capital); senior management and legal counsel were present. The vote will determine control-related governance changes and the company’s post-transaction structure, outcomes that are material to shareholders and could meaningfully affect CureVac’s strategic direction and valuation.

Analysis

Market structure: BioNTech’s public exchange offer for CureVac is a consolidation event that directly benefits BNTX (platform scale, IP, pipeline breadth) and CureVac holders who capture the deal premium; smaller pure‑play mRNA developers (e.g., MRNA) and niche CDMO providers stand to lose relative pricing power and fundraising optionality. Expect modest upward pressure on BNTX pricing power for mRNA therapeutics over 12–36 months and reduced platform fragmentation; short-term liquidity flows will concentrate in CVAC and BNTX equities and options, raising implied vol by +20–50% around key votes and regulatory filings.

Risk assessment: Primary tail risks are regulatory/antitrust blocks in EU or Germany, hostile minority shareholder litigation, and financing dilution if BNTX issues >10% new equity; failure scenarios could crater CVAC by >40% from offer-premium levels and pressure BNTX down 10–25% on dilution fears. Timing: immediate (days) — shareholder vote outcomes and spread compression; short-term (0–3 months) — antitrust / financing announcements; long-term (12–36 months) — integration and pipeline readouts determine realized synergies. Hidden dependencies include contingent IP licenses, employee retention clauses, and government vaccine policy that can materially alter deal value.

Trade implications: Primary actionable strategy is merger‑arb: long CVAC at a discount to implied offer value with a paired hedge in BNTX sized to the announced exchange ratio (or 50–75% notional if ratio unknown) to neutralize market beta; target capture within 3–9 months, hard stop 8–12% below entry. Options play: buy CVAC 6–12 month calls to lever arb while selling short‑dated BNTX calls to finance premium if implied vol skew favors CVAC; limit position to 1–3% NAV. Sector rotation: underweight small mRNA pure plays (MRNA) by 1–2% and reallocate into diversified vaccine leaders (PFE) or selective biotech names with cash runway >24 months.

Contrarian angles: Consensus assumes clean regulatory path and easy integration — that is underpriced. Missing is the political/regulatory sensitivity to national vaccine champions and the potential for complex earn‑outs tied to pipeline milestones; if financing steps involve >10% BNTX equity, downside for BNTX is underappreciated and CVAC arb becomes binary. Historical parallels (large platform consolidations in 2019–2021) show deals can take 6–18 months to close and arbitrage spreads widen before resolution, creating opportunities to scale into positions when spread >7–10%.

Key Decisions for Investors

• Merger arb: Establish a 2–3% NAV long position in CVAC if trading ≥3% below the implied offer value (or spread ≤10%), hedge market exposure by shorting BNTX ~50–75% notional (until exchange ratio is confirmed); target capture in 3–9 months, set stop‑loss 10% below entry.
• Event‑driven options: Buy CVAC Jan 2026 (6–12 month) calls sized to 0.5–1% NAV if implied vol is <60% and sell 30–45 day BNTX calls to finance premium (sell only if delta neutral criteria met); close if antitrust filing occurs within 60 days or if implied vol spikes >80%.
• Risk reduction: Reduce exposure to pure‑play mRNA developer MRNA by 1–2% NAV and reallocate that weight to PFE (overweight 1–2% NAV) for diversified vaccine exposure and lower execution risk over 12–36 months.
• Trigger monitoring: If BioNTech announces equity financing >10% or if EU/German regulators open a formal probe within 30–60 days, reduce/close CVAC long and add a 1% short position in BNTX (anticipate 10–25% downside); conversely, if regulatory clearances proceed without conditions after 90 days, increase CVAC arb size by 50%.